SCHEMBL10020194

SCHEMBL10020194

CCCCc1c(OCCC)n(C)c(=O)n(C)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 3/20 0.51
MAPK1 P28482 1/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 3/20 0.36
ADORA2A P29274 3/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
CYP1A2 P05177 2/20 0.33
CYP2C19 P33261 2/20 0.33
RECQL P46063 1/20 0.33
NCOA1 Q15788 1/20 0.33
NCOA3 Q9Y6Q9 1/20 0.33
SIRT1 Q96EB6 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27735143 0.75 AOC3 (0.46) AOC3MAPK1USP2CYP1A2RECQL
SCHEMBL10838932 0.73 CYP1A2 (0.43) ALDH1A1CYP1A2CYP2C19RECQLSIRT1
SCHEMBL17070902 0.73 KDM4E (0.51) AOC3MAPK1ALDH1A1CYP1A2CYP2C19
SCHEMBL25100422 0.71 CA12 (0.42) ALDH1A1MAOBCYP1A2CYP2C19NCOA1
SCHEMBL2210503 0.68 AOC3 (1.00) AOC3MAPK1USP2ALDH1A1ADORA2A
SCHEMBL16735525 0.68 AOC3 (1.00) AOC3MAPK1USP2ALDH1A1ADORA2A
SCHEMBL2210507 0.68 AOC3 (1.00) AOC3MAPK1USP2ALDH1A1ADORA2A
SCHEMBL23400903 0.61 NPC1 (0.39) ALDH1A1SIRT1KDM4E
SCHEMBL12280422 0.60 AOC3 (0.65) AOC3USP2ALDH1A1CYP1A2CYP2C19
SCHEMBL23400049 0.60 TYMP (0.37) ALDH1A1SIRT1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120226067-A1 PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS MARSAULT ERIC (CA) 2012-09-06 US disclosed
US-20120165566-A1 PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS MARSAULT ERIC (CA) 2012-06-28 US disclosed
US-20110288163-A1 METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR MALLINCKRODT US HOLDINGS LLC 2011-11-24 US disclosed
US-7521420-B2 Macrocyclic antagonists of the motilin receptor TRANZYME PHARMA, INC. (CA) 2009-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288163-A1 METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR GHSR, GHRHR, GIPR AOC3 1950/4885MAPK1 1428/4885USP2 2518/4885
US-20120165566-A1 PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS MLNR, CHRM2, CHRM1 AOC3 1799/4885MAPK1 1445/4885USP2 4503/4885
US-20120226067-A1 PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS MLNR, CHRM2, CCKAR AOC3 1618/4885MAPK1 1435/4885USP2 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.